In a test-negative design case-control study, Dr. Thiago Cerqueira-Silva and colleagues, investigate the effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland.